Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2018
- Type
- Corporation Seattle business license
- Employees
- 51
- Registered name
- HDT Bio Corp Seattle business license
- Stage
- Clinical-stage
- Founders
- Andre Lieber
Is this your organization? Claim it
Seattle Biotech Myosana Raises $5M to Develop Advanced Gene Therapy for Duchenne Muscular Dystrophy
Myosana Therapeutics, a Seattle biotech co-founded by University of Washington researchers, raised $5 million to advance a novel gene therapy candidate targeting Duchenne muscular dystrophy (DMD). The company aims to develop a gene delivery platform that can handle larger DNA segments compared to current standard methods, potentially improving treatment options against DMD.
Seattle Startup Curevo Raises $26M to Develop Shingles Vaccine Rivaling GSK’s $2.3B Shingrix
Seattle vaccine startup Curevo raised $26 million to advance its shingles vaccine CRV-101, competing against GSK's $2.3 billion Shingrix vaccine with a potentially safer, equally effective alternative. Curevo completed enrollment in a Phase 2b trial comparing CRV-101 to Shingrix, with results expected in early 2023.
Seattle Startup HDT Bio Secures $1.8M U.S. Army Grant to Develop Broad-Spectrum Antiviral Nasal Spray by 2025
Seattle startup HDT Bio received a nearly $1.8 million U.S. Army grant to develop a nasal spray using proprietary RNA technology that targets a broad range of respiratory viruses, with clinical trials expected to begin in 2025. The spray aims to prevent virus replication and transmission and could be used by both military personnel and civilians.
See all 7 stories, episodes and videos about HDT Bio.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
André Lieber Scientific Co-Founder
-
Steven Reed Co-Founder & CEO